Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

BioStock: Curasight CEO reflects on a Q3 with strong progress

Curasight

Curasight recently released its Q3 report, reflecting on a period of good momentum. Publishing complete phase II results with uTRACE in brain cancer, the company announced that the indication will be the target for a first-in-human trial with uTREAT. Following the oversubscribed rights issue in September, further funding for the study is added through the exercise of the TO 2 warrants. BioStock contacted CEO Ulrich Krasilnikoff for his thoughts.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/11/curasight-ceo-reflects-on-a-q3-with-strong-progress/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.